<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:aavptbiennial-ojs-tamu.tdl.org:article/36</identifier>
				<datestamp>2022-06-28T18:25:57Z</datestamp>
				<setSpec>aavptbiennial:S4</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Population Variability in Animal Health: Influence on Dose-Exposure-Response Relationships or Withdrawal Times</dc:title>
	<dc:creator xml:lang="en">Martinez, Marilyn N.</dc:creator>
	<dc:subject xml:lang="en">population variability</dc:subject>
	<dc:subject xml:lang="en">drug absorption</dc:subject>
	<dc:subject xml:lang="en">metabolism</dc:subject>
	<dc:subject xml:lang="en">disposition</dc:subject>
	<dc:subject xml:lang="en">clearance</dc:subject>
	<dc:description xml:lang="en">During the Tuesday AAVPT session, the issue of population variability in animal health will be explored from the perspective of what is known and the tools available to evaluate this variability. Sessions include the following topics:• Drug metabolism polymorphisms in dogs and cats, Michael Court• Age effects, Danielle Mzck• Companion animal transporter polymorphisms, Katrina Mealey• Food animal transporter polymorphisms, Johanna Fink-Gremmels• Modeling and simulation: shifting gears to accelerate understanding of variability in animal health, Jonathan Mochel• Top down versus bottom up modeling approaches, Ronette Gehring• Modeling and simulation to understand diversity in residues, Jim Riviere• Modeling and simulation to improve clinical trials, Tomas Martin-Jimenez• Understanding differences in dose-exposure relationships as a function of drug formulation and dog breed, Devendra Pade• Practical implications to industry, Ludwig PelligandThese talks will be summarized for publication as a review article to be submitted to the Journal of Veterinary Pharmacology and Therapeutics. Therefore, separate abstracts for these presentations were not requested from the speakers.</dc:description>
	<dc:publisher xml:lang="en">AAVPT Biennial Symposia</dc:publisher>
	<dc:date>2017-05-22</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://aavptbiennial-ojs-tamu.tdl.org/aavptbiennial/article/view/36</dc:identifier>
	<dc:source xml:lang="en">AAVPT Biennial Symposia; 20th Biennial Symposium</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://aavptbiennial-ojs-tamu.tdl.org/aavptbiennial/article/view/36/35</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2017 American Academy of Veterinary Pharmacology and Therapeutics</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
